Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Earnings Call

EyePoint Earnings Call: Key Takeaways

EyePoint is pivoting to Diabetic Macular Edema (DME) after Phase 3 Wet AMD trials failed, implementing a 53% workforce reduction to preserve cash.

Full earnings call on the Alfa Finder USA YouTube channel · Open on YouTube ↗
Highlights
Mgmt ConfidenceDeeply disappointed by Wet AMD results; confident in DME's distinct biological rationale.
Demand VisibilityDME market includes 50% working-age adults with high treatment discontinuation rates.
Margin TrendsTargeting $30 million in annualized savings through workforce and cost reductions.
Op. LeverageReducing workforce by 53% to align cost structure with strategic priorities.
Segment GrowthDiscontinuing Wet AMD; focusing all resources on DME clinical programs.
Capex & Debt$118 million cash balance; evaluating levers to extend runway past Q3 2027.
RegulatoryDME trial protocol amended to tighten rescue criteria for non-inferiority protection.
CommentaryStrategic pivot to DME leveraging multi-mechanism JAK-1 and VEGF inhibition profile.
New LaunchesDUR-VUE Phase 3 trials (Como and Capri) currently enrolling 550+ patients.

Growth

DME market is $5B globally; $3B in US. Wet AMD program discontinued entirely.

Outlook

Top-line results for Como and Capri DME trials expected early Q4 2027.

Risks

Cash runway only extends to late Q3 2027; top-line DME data expected Q4 2027.

Source

The company's earnings call, NASDAQ: EYPT, and its 8-K filed with the SEC. Summary written with AI assistance from the call.

Read the 8-K ↗

EyePoint, Inc.: key numbers

Share price
$0.3076Close, Nov 16
Market cap
$35M
Shares outstanding
113.78MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Laboratory Analytical InstrumentsSIC 3826

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from EyePoint, Inc.

All →
4:08 PM ET 10-Q
Financial Results ▶ Call

EyePoint Q3 2026 Results: Net Loss of $95.6M, Loss Widens

EyePoint, Inc. reported a significant increase in net loss to $274.9 million for the nine months ended September 30, 2026, driven primarily by a surge in research and development expenses to $237.4 million. Total revenues declined sharply from $30.8 million to $2.0 million year-over-year, largely due to the absence of significant license and collaboration revenue seen in 2025.

Key figure
Net loss $95.6M
7:05 AM ET 8-K
Financial Results

EyePoint Financial Results

EyePoint reported Q3 2026 financial results and announced a strategic prioritization of its DURAVYU Phase 3 program in Diabetic Macular Edema (DME). The company expects this prioritization to generate $30 million in annualized savings following mixed Phase 3 results in wet AMD.

“The recent Phase 3 wet AMD data demonstrated DURAVYU’s ability to control fluid and maintain retinal anatomy through Week 56, along with a favorable safety profile that included every six-month redosing. This important data supports our strategic decision to prioritize our resources on DME, where we believe there is strong scientific and clinical rationale for DURAVYU as a durable treatment option for this vision threatening exudative disease.”

Jay S. Duker, M.D., President and Chief Executive Officer of EyePoint
9:22 AM ET 8-K
Business Update

EyePoint Business Update

EyePoint is implementing a strategic prioritization plan that includes a 53% workforce reduction and the early conclusion of its Phase 3 wet AMD clinical trials after the LUCIA study failed to meet its primary endpoint. The company will focus its remaining resources on the development of DURAVYU for diabetic macular edema (DME), expecting to save approximately $30 million annually while incurring $9 million in one-time restructuring charges.

7:05 AM ET 8-K
Clinical Trial Data

EyePoint Clinical Trial Data

EyePoint announced topline results from LUCIA, its second pivotal Phase 3 clinical trial of DURAVYU for wet age-related macular degeneration (wet AMD). The trial failed to meet its primary endpoint of statistical non-inferiority in mean change in best corrected visual acuity (BCVA) compared to the aflibercept control, although it did meet secondary endpoints related to treatment burden reduction and safety.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.